In the past week, Bristol-Myers Squibb Co’s BMY 1.87% loss has been Merck & Co., Inc.’s MRK 0.4% gain.

When Bristol-Myers reported back on August 5 that Opdivo did not meet its targets for treatment of advanced non-small cell lung cancer, the stock tanked 16 percent. Merck stock, on the other hand spiked 10.4 percent on the news as investors speculated that the company’s rival drug Keytruda could be the big winner.

However, the stock’s performances have continued to mirror each other ever since, as PreMarket Prep’s Dennis Dick pointed out on Twitter.

One likely explanation is that a number of traders have been pair trading the stocks ever since the Opdivo news came out. For Now, Bristol-Myers seems to have found some support at the $60 level, but a breakout below $60 would likely push the stock to test the $55-58 level where it found support in late 2015 and early 2016. A Bristol-Myers breakdown could also trigger…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!